Pharma bets billions on AI drug discovery despite human-body validation risk

Pharmaceutical companies are investing heavily in AI to identify promising drug molecules, but the technology's output still faces the ultimate test of clinical efficacy in humans. The article highlights the gap between AI-driven predictions and real-world therapeutic success, underscoring the financial risk of this trust credit. This reflects a broader industry trend toward AI adoption in R&D, with uncertain returns.